Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases

Affiliations

Comparative Study

Eugen Javor et al. JAMA. 2022.

. 2022 Apr 19;327(15):1505-1506.

doi: 10.1001/jama.2022.2935.

No abstract available

Comment in

Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy and Control of Immune-Mediated Inflammatory Diseases-Reply.
Syversen SW, Jahnsen J, Haavardsholm EA. Syversen SW, et al. JAMA. 2022 Apr 19;327(15):1506-1507. doi: 10.1001/jama.2022.2938. JAMA. 2022. PMID: 35438729 No abstract available.

Effect of Therapeutic Drug Monitoring vs Standard Therapy During Maintenance Infliximab Therapy on Disease Control in Patients With Immune-Mediated Inflammatory Diseases: A Randomized Clinical Trial.
Syversen SW, Jørgensen KK, Goll GL, Brun MK, Sandanger Ø, Bjørlykke KH, Sexton J, Olsen IC, Gehin JE, Warren DJ, Klaasen RA, Noraberg G, Bruun TJ, Dotterud CK, Ljoså MKA, Haugen AJ, Njålla RJ, Zettel C, Ystrøm CM, Bragnes YH, Skorpe S, Thune T, Seeberg KA, Michelsen B, Blomgren IM, Strand EK, Mielnik P, Torp R, Mørk C, Kvien TK, Jahnsen J, Bolstad N, Haavardsholm EA. Syversen SW, et al. JAMA. 2021 Dec 21;326(23):2375-2384. doi: 10.1001/jama.2021.21316. JAMA. 2021. PMID: 34932077 Free PMC article. Clinical Trial.